Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer
Mol Cancer Ther. 2009 Jan;8(1):194-202. doi: 10.1158/1535-7163.MCT-08-0659.ABSTRACTOxaliplatin…
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
Eur J Cancer. 2008 Jun;44(9):1229-37. doi: 10.1016/j.ejca.2008.03.025.…
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan
Oncol Rep. 2007 Mar;17(3):637-45.ABSTRACTThe aim of this study…
Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells
Int J Oncol. 2006 Jul;29(1):225-35. doi: 10.3892/ijo.29.1.225.ABSTRACTThe…
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines
Invest New Drugs. 2004 Nov;22(4):399-409. doi: 10.1023/B:DRUG.0000036682.99818.71.ABSTRACTPURPOSE:…
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism
Invest New Drugs. 2003 Nov;21(4):435-43. doi: 10.1023/a:1026251202137.ABSTRACTPURPOSE:…
Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms
Int J Oncol. 2003 May;22(5):945-53. doi: 10.3892/ijo.22.5.945.ABSTRACTThymidylate…
